Dr. Anne Koralova is a Program Officer for the Helmsley Charitable Trust’s Type 1 Diabetes (T1D) Program. She helps to oversee the current research grants portfolio and identify and validate new opportunities with a particular focus on the area of T1D prevention.
Prior to joining Helmsley, Anne was the associate director of translational initiatives and business strategies in the Office of Therapeutics Alliances at NYU Langone Medical Center. There she directed the activities of the Translational Science Incubator program, assisted in developmental funding decisions, and helped to identify and develop internal translational research groups to capitalize on NYU discoveries. Previously, Anne worked in biotechnology and pharmaceuticals consulting on a variety of indications across the drug development lifecycle. She was also a group leader of the biotechnology and pharmaceuticals practice at an intellectual property research firm, where she managed projects across a wide array of technologies.
Anne earned a Ph.D. from the biological and biomedical sciences program at Harvard Medical School and a Bachelor of Science in biology from the Massachusetts Institute of Technology.